Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

  • Codony-Servat, Jordi
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Asensio, Elena
  • Montironi, Carla|||0000-0002-1453-2193
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Marín Aguilera, Mercedes
  • Horndler, Carlos
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Rubini, Michele
  • Jares, Pedro
  • Reig, Oscar|||0000-0003-1166-6943
  • Victoria, Iván
  • Gaba, Lydia
  • Martín-Richard, Marta|||0000-0003-4933-2463
  • Alonso Orduña, Vicente|||0000-0003-2280-1004
  • Escudero, Pilar
  • Fernández-Martos, Carlos
  • Feliu, Jaime|||0000-0003-4867-1420
  • Méndez, Jose Carlos
  • Méndez, Miguel
  • Gallego Plazas, Javier|||0000-0002-0584-1242
  • Salud, Antonieta
  • Rojo, Federico|||0000-0001-9989-0290
  • Castells, Antoni|||0000-0001-8431-2033
  • Prat, Aleix|||0000-0003-2377-540X
  • Rosell, Rafael|||0000-0003-0817-3400
  • García-Albéniz, Xabier
  • Camps Polo, Jordi|||0000-0003-2929-4228
  • Maurel, Joan|||0000-0002-9413-5592
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of CRC and RNAi for functional validation. Nuclear IGF-1R increased in metastatic tumours compared to paired untreated primary tumours, and significantly correlated with poor overall survival in mCRC patients. In vitro, chemo-resistant cell lines presented significantly higher levels of IGF-1R expression within the nuclear compartment, and PIAS3, a protein implicated also in the sumoylation process of intranuclear proteins, contributed to IGF-1R nuclear sequestration, highlighting the essential role of PIAS3 in this process. Intriguingly, we observed that ganitumab, an IGF-1R blocking-antibody used in several clinical trials, and dasatinib, an SRC inhibitor, increased the nuclear localisation of IGF-1R. Our study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

  • Rodríguez, Adela|||0000-0002-4899-6607
  • Esposito, Francis|||0000-0002-5028-9637
  • Oliveres, Helena|||0000-0003-1801-1181
  • Torres, Ferran|||0000-0002-7355-7913
The approval of a new drug for cancer treatment by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is based on positive, well-designed randomized phase III clinical trials (RCTs). However, not all of them are analyzed to support the recommendations. For this reason, there are different scales to quantify and evaluate the quality of RCTs and the magnitude of the clinical benefits of new drugs for treating solid tumors. In this review, we discuss the value of the progression-free survival (PFS) as an endpoint in RCTs and the concordance between it and the overall survival (OS) as a measure of the quality of clinical trial designs. We summarize and analyze the different scales to evaluate the clinical benefits of new drugs such as the The American Society of Clinical Oncology value framework (ASCO-VF-NHB16) and European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the concordance between them, focusing on metastatic colorectal cancer (mCRC). We propose several definitions that would help to evaluate the quality of RCT, the magnitude of clinical benefit and the appropriate approval of new drugs in oncology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab, the BEYOND study (GEMCAD 17-01)

  • Aparicio Urtasun, Jorge
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Capdevila Castillón, Jaume|||0000-0003-0718-8619
  • Muñoz Boza, F.
  • Galván, Patricia
  • Richart, P.
  • Oliveres, H.
  • Paez, David|||0000-0002-5596-6588
  • Hernando Cubero, Jorge
  • Serrano, S.
  • Vera, Ruth|||0000-0003-1524-3147
  • Hernandez-Yagüe, X.
  • Gallego, R.Á.
  • Riesco-Martinez, M.C.
  • García de Albeniz, X.
  • Maurel, Joan|||0000-0002-9413-5592
Purpose: Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge is currently unknown. We assessed addition of panitumumab to FOLFIRI (P-FOLFIRI) beyond progression to P-FOLFOX in patients with no RAS mutations in liquid biopsy (LB). Methods: In this randomized phase II trial, patients were assigned (3:2 ratio) to second-line P-FOLFIRI (arm A) or FOLFIRI alone (arm B). LB for circulating tumor DNA analysis was collected at study entry and at disease progression. Primary endpoint was 6-month progression-free survival. Two-stage Simon design required 85 patients to be included (EudraCT 2017-004519-38). Results: Between February 2019 and November 2020, 49 patients were screened (16 RAS mutations in LB detected) and 31 included (18 assigned to arm A and 13 to arm B). The study was prematurely closed due to inadequate recruitment. Serious adverse events were more frequent in arm A (44% vs. 23%). Overall response rate was 33% (arm A) vs. 7.7% (arm B). Six-month progression-free survival rate was 66.7% (arm A) and 38.5% (arm B). Median progression-free survival was 11.0 months (arm A) and 4.0 months (arm B) (hazard ratio, 0.58). At disease progression, RAS or BRAF mutations in LB were found in 4/11 patients (36%) in arm A and 2/10 (20%) in arm B. Conclusions: The BEYOND study suggests a meaningful benefit of P-FOLFIRI beyond progression to P-FOLFOX in metastatic colorectal cancer patients with WT RAS status selected by LB. This strategy deserves further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients, GEMCAD 1602 study

  • Español-Rego, Marta|||0000-0001-5497-2276
  • Fernández-Martos, Carlos
  • Elez, Elena|||0000-0002-4653-6324
  • Foguet, Carles
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Rodríguez, Nuria
  • Ruiz-casado, Ana
  • Pineda, Estela|||0000-0003-2128-747X
  • Cid, Joan|||0000-0001-5445-4508
  • Cabezón, Raquel
  • Oliveres, Helena|||0000-0003-1801-1181
  • Lozano, Miquel|||0000-0003-2593-833X
  • Ginés, Angels
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Ayuso Colella, Juan Ramón|||0000-0002-5306-6850
  • Pagés, Mario
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Torres, Ferran|||0000-0002-7355-7913
  • Thomson, Timothy
  • Cascante, Marta
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Torres, Ferran|||0000-0002-7355-7913
Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects. This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage. A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1-5.3 months] and overall survival was 12.2 months [3.2-23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways. The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities. The online version contains supplementary material available at 10.1007/s00262-022-03283-5.